Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters

Nov 10

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582690873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582690873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582690873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582690873","market":"nz","top_or_hot":-1,"title":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9Sxsb:1","article_id":"2582690873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582690873","pubTimestamp":1762776121,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA  will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology , taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma  with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4539":"次新股","DAWN":"Day One Biopharmaceuticals Inc.","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Day One Biopharmaceuticals报告OJEMDA在儿童低级别神经胶质瘤试验中的持久反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":0.9,"NDAQ":0.9},"content_text":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    \n\nDay One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}